Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02078726 · ClinicalTrials.gov registry record · Phase 4
Glucagon Use in Colonoscopies
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT02078726 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 100 participants.
The verdict
NCT02078726, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.
Interventions
- DRUG Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02078726
The ClinicalTrials.gov registry entry for NCT02078726 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glucagon is the first listed.
NCT02078726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02078726 about?
NCT02078726 is a clinical study titled "Glucagon Use in Colonoscopies". The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willi...
What is the current status of trial NCT02078726?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2014-04. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02078726?
The interventions under investigation include: Glucagon (DRUG).
Who is sponsoring clinical trial NCT02078726?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.